Synthetic Antibody-Rhamnose Cluster Conjugates Show Potent Complement-Dependent Cell Killing by Recruiting Natural Antibodies

Chemistry. 2022 Mar 16;28(16):e202200146. doi: 10.1002/chem.202200146. Epub 2022 Feb 21.

Abstract

Monoclonal antibodies (mAbs) are one of the most rapidly growing drug classes used for the treatment of cancer, infectious and autoimmune diseases. Complement-dependent cytotoxicity (CDC) is one of the effector functions for antibodies to deplete target cells. We report here an efficient chemoenzymatic synthesis of structurally well-defined conjugates of a monoclonal antibody with a rhamnose- and an αGal trisaccharide-cluster to recruit natural anti-rhamnose and anti-αGal antibodies, respectively, to enhance the CDC-dependent targeted cell killing. The synthesis was achieved by using a modular antibody Fc-glycan remodeling method that includes site-specific chemoenzymatic Fc-glycan functionalization and subsequent click conjugation of synthetic rhamnose- and αGal trisaccharide-cluster to provide the respective homogeneous antibody conjugates. Cell-based assays indicated that the antibody-rhamnose cluster conjugates could mediate potent CDC activity for targeted cancer cell killing and showed much more potent efficacy than the antibody-αGal trisaccharide cluster conjugates for CDC effects.

Keywords: anti-Rha antibody; antibody conjugates; chemoenzymatic synthesis; glycoengineering; immunotherapy.

MeSH terms

  • Antibodies, Monoclonal
  • Apoptosis
  • Immunoconjugates*
  • Immunoglobulin Fc Fragments
  • Rhamnose*

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • Immunoglobulin Fc Fragments
  • Rhamnose